There are two completely different things people mean when they type “peptides for weight loss” into a search bar, and the gap between them is the reason this topic is so confusing.
One is collagen peptides: the hydrolyzed protein powder in the tub next to the whey at the supplement store. Those do almost nothing for weight loss on their own, despite the marketing. The other is a class of injectable compounds that have produced some of the largest weight-loss numbers ever recorded in a clinical trial. Same word. Wildly different things. This guide is about the second category, with a clear line drawn so you don’t waste money on the first by accident.
If you’ve heard about Ozempic, Mounjaro, or the newer compound everyone keeps calling “the triple agonist,” you already know more about weight loss peptides than you think. You just didn’t know those drugs were peptides. Most of them are.
A note before we start, because it matters for how you should read everything below: we sell these as research chemicals for laboratory use, not as medicine, and we don’t make medical claims. What this article does is report what the published trials actually measured. The real percentages, the timeframes, and the parts the trials are honest about that the marketing tends to skip.
What Are Peptides for Weight Loss, Exactly?
A peptide is a short chain of amino acids — the same stuff protein is made of, just in a specific short sequence your body or a lab can build. Some peptides happen to interact with the systems that control hunger, insulin, and how your body decides whether to store or burn energy.
The ones driving the entire weight-loss conversation right now are GLP-1 receptor agonists and their newer multi-target cousins. GLP-1 (glucagon-like peptide-1) is a hormone your gut already releases after you eat. It tells your pancreas to release insulin, slows how fast your stomach empties, and signals your brain that you’re full. The drug versions are engineered to do the same thing, but last days instead of minutes.
That’s the whole mechanism, in plain terms: these compounds make you feel full sooner and stay full longer, while improving how your body handles blood sugar. Everything else (the trial numbers, the side effects, the comparisons below) flows from that.
What they are not is a fat-dissolving injection or a metabolism “hack.” The weight comes off mostly because people eat substantially less, without the white-knuckle hunger that usually sabotages a diet. Worth knowing up front, because it shapes what realistic results look like.
The GLP-1 Class: Semaglutide, Tirzepatide, Retatrutide
These three are the headline acts. They’re related but not interchangeable, and the differences are bigger than the marketing suggests.
Semaglutide
Semaglutide is the one you’ve heard of under the brand names Ozempic and Wegovy. It’s a single-target GLP-1 agonist. It does the one thing described above, and does it well.
In the STEP-1 trial, participants lost a mean of about 14–15% of body weight at 68 weeks on the higher weight-management dose, versus roughly 2–3% on placebo. That’s a genuinely large number for this kind of intervention. The previous generation of comparable compounds struggled to clear 5–10%.
The caveat the trial is honest about: a meaningful share of that lost weight isn’t fat. More on that further down, because it’s the single most important thing the marketing leaves out.
Tirzepatide
Tirzepatide (Mounjaro, Zepbound) hits two receptors — GLP-1 and GIP, a second gut hormone. The two-target approach turned out to matter.
In SURMOUNT-1, tirzepatide produced roughly 20–22.5% mean weight loss at 72 weeks at the top dose. And in SURMOUNT-5, a head-to-head against semaglutide, tirzepatide came out ahead, about 20.2% versus 13.7%. When people search “semaglutide vs tirzepatide,” that trial is the short answer: in the direct comparison, the dual agonist won on weight loss. It also tends to bring more gastrointestinal side effects along with it, which is the trade most people don’t price in.
Retatrutide
Retatrutide is the one biohacker forums won’t stop talking about. It’s a triple agonist — GLP-1, GIP, and glucagon — and the early data is the reason for the noise.
Here’s the dose-response ladder from the Phase 2 trial, because the staircase tells the story better than any single number: roughly −8.7% at the 1mg dose, −17.1%, −22.8%, and −24.2% at 12mg over 48 weeks, against about −2.1% for placebo. An endocrinologist quoted on the results called it “way beyond my wildest dreams.” Another, in the same coverage, called it “not a magic pill.” Both things are true.
The line that matters more than the percentage: retatrutide is Phase 2 and investigational. It is not an approved drug. The 24% figure comes from a single mid-stage trial. Phase 3 is still running. Anyone presenting retatrutide as a finished, validated product is ahead of the evidence, and that’s worth noticing, because it tells you something about the source.
Cagrilintide and the Combination Story
Cagrilintide is a different mechanism — an amylin analog, mimicking a hormone that works alongside insulin on satiety. On its own, the weight-loss effect is real but modest compared to the GLP-1s.
The reason it gets attention is the combination. Paired with semaglutide (the trial combination is called CagriSema), the early results stack toward the tirzepatide range. That’s the actual story with cagrilintide: it’s a combination play, still in trials, not a standalone answer. If a vendor is selling it to you as a complete solution by itself, they’re skipping that context.
The Second Tier: AOD-9604, Fragment 176-191, MOTS-C, Tesofensine
This is where honesty separates a useful guide from marketing copy. These compounds get sold in the same breath as the GLP-1s. They do not belong in the same conversation, and pretending otherwise is the single biggest red flag in this whole product category.
AOD-9604 is a fragment of growth hormone studied for fat metabolism. The best human data showed something like 2.6 kg lost versus 0.8 kg on placebo over 12 weeks, and a larger, longer trial of roughly 536 subjects over 24 weeks failed to hit its endpoint. It’s not a fraud. It’s just not a GLP-1. If you’re comparing it to semaglutide’s numbers, it isn’t even in the same category.
HGH Fragment 176-191 gets sold as AOD-9604’s cousin. It has essentially no independent human efficacy data. The claims made for it are extrapolated from AOD-9604 research. A compound with no human data of its own, marketed as if it does, is exactly the pattern to be suspicious of.
MOTS-C is a fascinating mitochondrial-derived peptide with genuine research interest in metabolism and exercise biology. For fat loss specifically, the evidence is essentially preclinical — animal and cell models. Interesting science, early stage, not a weight-loss result you can bank on.
Tesofensine showed around 10% weight loss in a Phase 2 trial, then stalled in development and was never approved. Promising once, parked now. Not available as a finished therapy, and not in the same evidentiary tier as the approved GLP-1s.
The honest summary: there is the GLP-1 family, which has produced large, replicated, peer-reviewed weight-loss numbers, and there is everything else, which ranges from “modest and mixed” to “no human data at all.” A guide that flattens that distinction is selling, not informing.
Best Peptides for Weight Loss — Honest Comparison
If you skipped to this section looking for the shortlist, here it is — but read the efficacy column with the trial context above, not as a leaderboard.
| Compound | Mechanism | Best evidence | Status | Honest read |
|---|---|---|---|---|
| Semaglutide | GLP-1 | ~14–15% at 68 wks (STEP-1) | Approved drug | The proven baseline |
| Tirzepatide | GLP-1 + GIP | ~20–22.5% at 72 wks; beat sema head-to-head | Approved drug | Strongest approved option |
| Retatrutide | GLP-1 + GIP + glucagon | ~24% at 48 wks (Phase 2) | Investigational | Highest numbers, least finished |
| Cagrilintide | Amylin analog | Modest alone; strong in combo | Trial-stage | A combination play |
| AOD-9604 | GH fragment | ~2.6 kg vs 0.8 kg / 12 wks; larger trial failed | Research compound | Not in the GLP-1 class |
| MOTS-C | Mitochondrial peptide | Preclinical for fat loss | Research compound | Early-stage science |
| Tesofensine | Triple monoamine reuptake | ~10% Phase 2, stalled | Not approved | Promising once, parked |
The pattern is hard to miss: the approved GLP-1 drugs are a tier of their own. Everything below the line is research-stage, mixed, or preliminary. The “best peptide for weight loss” question has a boring answer — the ones with the biggest, most replicated trials — and most of the internet’s excitement is about the compounds with the least data.
The Part the Marketing Skips: Lean Mass
This is the most important section in the article, and it’s the one you’ll almost never see on a vendor page.
When people lose 15–25% of their body weight on a GLP-1, roughly a quarter to 40% of that loss is lean mass: muscle, not fat (this shows up across STEP-1, SUSTAIN-8, and is consistent enough that it’s now consensus, not a fringe worry). You lose the weight, but you also lose a chunk of the metabolically active tissue you’d rather keep.
This isn’t an argument against the drugs. It’s the reason every credible source pairs the conversation with resistance training and higher protein intake. Peter Attia has written about this at length. The weight-loss number on the box is real; the body-composition reality underneath it is more complicated, and a guide that doesn’t tell you that isn’t being straight with you. If muscle retention is the goal alongside fat loss, the peptides studied for muscle growth sit on the other side of that same equation.
Oral vs Injectable
Almost all of the compounds with serious weight-loss data are injectable. Oral GLP-1 versions exist (oral semaglutide is real), but the injectable forms are what nearly every headline trial used.
Searches for “oral peptides for weight loss” mostly run into this wall: the convenient oral options are either lower-absorption versions of the injectables or unproven compounds riding the category’s coattails. The needle is inconvenient. It’s also where the evidence is. That’s the honest trade, and no amount of “peptides pills for weight loss” marketing changes it.
Side Effects and Safety
The GLP-1 class has a consistent side-effect profile in the trials. It’s mostly gastrointestinal: nausea, vomiting, diarrhea, constipation, usually worst when the dose steps up and often settling down over time. Tirzepatide and retatrutide tend to bring more of it than semaglutide, which tracks with their stronger effect. There are rarer concerns the trial literature documents, which is exactly why the approved versions are prescription drugs and not supplements.
When people ask “are peptides safe for weight loss,” the honest answer has two halves. The approved GLP-1 drugs have large safety datasets from their trials. The second-tier compounds (fragment 176-191, MOTS-C for fat loss, the unproven stack) don’t have that, and “no reported problems” usually just means “no real studies looking.” Absence of data is not a safety record.
Peptides for Weight Loss for Women and Men
The trials enrolled both, and the headline efficacy numbers hold broadly across sexes. There isn’t a separate “weight loss peptide for women” or a different one for men in any pharmacological sense. The search terms exist because people search that way, not because the biology splits cleanly. The one consistent, evidence-backed nuance is the lean-mass point above: protein intake and resistance training matter for everyone on these compounds, and arguably more for anyone with less muscle to spare to begin with.
What About Canada?
This is a research-use-only supplier based in Canada, so the practical context: the approved versions of these compounds (semaglutide, tirzepatide) are prescription medicines, and search interest for “tirzepatide Canada” and “semaglutide Canada” is enormous and still climbing. What we supply are research-grade compounds for laboratory use, third-party tested. Not prescriptions, not medical advice, not a route around a clinician. The single highest-leverage thing for anyone evaluating a research compound isn’t which peptide. It’s whether what’s in the vial matches the label, which is why every product here ships with third-party Janoshik lab testing. Underdosed and mislabeled material is the norm in the gray market, not the exception.
Where This Actually Leaves You
The useful version of this whole article in five sentences: the GLP-1 family (semaglutide, tirzepatide, and the investigational retatrutide) has produced the largest, best-documented weight-loss numbers, in that rough order of how finished the evidence is. Tirzepatide beat semaglutide head-to-head. Retatrutide’s numbers are higher but Phase 2. A meaningful fraction of all that lost weight is muscle unless you train and eat for it. And nearly everything else marketed in this category, from collagen peptides to fragment 176-191, is either a different product entirely or running on far less evidence than the marketing implies.
If you want the deeper comparison of just the three GLP-1s, the tirzepatide vs semaglutide vs retatrutide breakdown goes dose-by-dose. And if reconstitution math is the part that’s actually stopping you, the dosage calculator does it for you.
Sources
- Wilding JPH, et al. New England Journal of Medicine. 2021. (STEP-1 — semaglutide 68-week weight management trial)
- Jastreboff AM, et al. New England Journal of Medicine. 2022. (SURMOUNT-1 — tirzepatide weight-loss trial)
- Aronne LJ, et al. New England Journal of Medicine. 2025. (SURMOUNT-5 — tirzepatide vs semaglutide head-to-head)
- Jastreboff AM, et al. New England Journal of Medicine. 2023. (Retatrutide Phase 2 — triple-agonist dose-response data)
- Frias JP, et al. Lancet. 2023. (Cagrilintide + semaglutide combination data)
- Heffernan M, et al. (AOD-9604 human clinical trial data — growth hormone fragment for fat metabolism)
- Attia P. peterattiamd.com. (Lean mass loss on GLP-1 receptor agonists — body-composition analysis)
- PubMed references for GLP-1 receptor agonists and weight loss
- PubMed references for tirzepatide
Related Reading
By the Peptigo Research Team · Published May 19, 2026 · 13 minute read
This article reports published clinical-trial research on compounds studied in metabolic research. Products discussed are sold as research chemicals for laboratory use only. They are not medications and nothing here is medical advice. Peptigo does not make medical claims. Consult a qualified clinician before any decision involving these compounds.